HLB Group to acquire 28.25% stake in PSMC for CAR-T drug development

HLB Group subsidiaries will acquire 30 billion won ($22.8 million) worth of equity in PSMC, a lead frame manufacturer, making HLB the largest shareholder with a 28.25% stake. PSMC will change its name to HLB innovation and add biopharmaceutical lines to develop CAR-T treatments.

“The HLB Group expressed its intention to acquire PSMC’s equity worth 30 billion won ($22.8 million) on Feb. 1.”koreabiomed.com

• 1 source
• koreabiomed.comPSMC emerges as core of HLB Group interested in CAR-T drugs < Bio < Article - KBRKim Chan-hyukFeb 27, 2023

Summarized from public sources; check the original articles before acting on it.